IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

metrics 2024

Unraveling the Complexities of Immune Responses to Drugs

Introduction

Immunopharmacology and Immunotoxicology, published by Taylor & Francis Ltd, is a distinguished academic journal with a focus on the interrelation between pharmacology, immunology, and toxicology. Established in 1978, the journal serves as a vital platform for the dissemination of cutting-edge research aimed at enhancing the understanding of immunologically mediated drug responses and toxic effects. The journal encompasses a broad scope of topics relevant to the fields of immunology, pharmacology, and toxicology, offering insights that are pivotal for both academia and the pharmaceutical industry. With a commendable 2023 impact factor and ranking in Q3 in Immunology and Q2 in both Pharmacology and Toxicology, it holds a respected position within its categories, making it a valuable resource for researchers, professionals, and students seeking to stay abreast of the latest developments in the field. The journal is accessible through traditional subscription models and encourages submissions that bring forth innovative findings that might influence therapeutic strategies and public health.

Metrics 2024

SCIMAGO Journal Rank0.68
Journal Impact Factor2.90
Journal Impact Factor (5 years)3.20
H-Index61
Journal IF Without Self2.90
Eigen Factor0.00
Normal Eigen Factor0.45
Influence0.61
Immediacy Index0.80
Cited Half Life6.70
Citing Half Life6.50
JCI0.71
Total Documents1769
WOS Total Citations2870
SCIMAGO Total Citations8556
SCIMAGO SELF Citations317
Scopus Journal Rank0.68
Cites / Document (2 Years)3.18
Cites / Document (3 Years)3.31
Cites / Document (4 Years)3.16

Metrics History

Rank 2024

Scopus

Toxicology in Pharmacology, Toxicology and Pharmaceutics
Rank #58/133
Percentile 56.39
Quartile Q2
Pharmacology in Pharmacology, Toxicology and Pharmaceutics
Rank #141/313
Percentile 54.95
Quartile Q2
Immunology and Allergy in Medicine
Rank #115/233
Percentile 50.64
Quartile Q2
Immunology in Immunology and Microbiology
Rank #133/236
Percentile 43.64
Quartile Q3

IF (Web Of Science)

IMMUNOLOGY
Rank 108/181
Percentile 40.60
Quartile Q3
PHARMACOLOGY & PHARMACY
Rank 147/354
Percentile 58.60
Quartile Q2
TOXICOLOGY
Rank 49/106
Percentile 54.20
Quartile Q2

JCI (Web Of Science)

IMMUNOLOGY
Rank 85/181
Percentile 53.04
Quartile Q2
PHARMACOLOGY & PHARMACY
Rank 162/354
Percentile 54.24
Quartile Q2
TOXICOLOGY
Rank 53/106
Percentile 50.00
Quartile Q3

Quartile History

Similar Journals

Journal of Ginseng Research

Pioneering Studies in Ginseng and Beyond
Publisher: KOREAN SOC GINSENGISSN: 1226-8453Frequency: 4 issues/year

Journal of Ginseng Research is a leading peer-reviewed publication dedicated to advancing the scientific knowledge and understanding of ginseng and its myriad applications in health and wellness. Published by KOREAN SOC GINSENG and located in the Netherlands, this open-access journal has been a pivotal resource for researchers, professionals, and students since its inception. With an impactful H-index and prestigious rankings in various categories, including Q1 in Biochemistry, Genetics and Molecular Biology, Biotechnology, Complementary and Alternative Medicine, and Plant Science, the journal stands at the forefront of interdisciplinary research in medicinal plants. The Scopus rankings further enhance its reputation, highlighting its position as the leading journal in Complementary and Alternative Medicine and among the top resources in related fields. Spanning research from 2010 to 2024, it offers a valuable platform for disseminating innovative findings, thus playing an essential role in shaping future studies on ginseng and similar botanicals.

IMMUNOLOGY LETTERS

Elevating Immunology: Where Research Meets Practice
Publisher: ELSEVIERISSN: 0165-2478Frequency: 12 issues/year

IMMUOLOGY LETTERS, published by Elsevier, is a distinguished journal in the field of immunology, focusing on the latest advancements and findings that significantly influence immunological research and clinical applications. Established in 1979, the journal has evolved to cater to a global readership, featuring high-quality peer-reviewed articles across a diverse spectrum of topics related to immunity and allergic responses. With an impressive Q2 category ranking in both Immunology and Allergy as of 2023, it holds a strong position within the scientific community, evidenced by its commendable Scopus rankings (Rank #71/233 in Medicine - Immunology and Allergy and Rank #85/236 in Immunology and Microbiology - Immunology). While primarily subscription-based, the journal aims to foster knowledge dissemination that encourages collaboration among researchers and practitioners alike, making significant contributions to the understanding of immune mechanisms. The journal is integral for educators, students, and professionals aiming to stay abreast of current trends and breakthroughs in the immune system's intricate functions.

ImmunoTargets and Therapy

Innovating Solutions for Immunological Challenges
Publisher: DOVE MEDICAL PRESS LTDISSN: Frequency: 1 issue/year

ImmunoTargets and Therapy is a leading open access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the field of immunology and its various therapeutic applications. Since its inception in 2012, the journal has rapidly become a vital resource for researchers, professionals, and students, achieving notable recognition with a Q1 ranking in both Immunology and Immunology and Allergy categories as of 2023. With an impressive Scopus ranking of #22 out of 233 in Medicine - Immunology and Allergy, and #25 out of 236 in Immunology and Microbiology, this journal maintains a 90th percentile standing in its field. ImmunoTargets and Therapy not only publishes original research articles, reviews, and clinical studies, but also fosters an inclusive platform for the dissemination of innovative findings critical to the fight against immunological disorders. Based in New Zealand, it serves a global audience, promoting knowledge exchange and collaboration through its open access model.

OncoImmunology

Innovating Immunotherapy for Tomorrow's Treatments
Publisher: TAYLOR & FRANCIS INCISSN: 2162-402XFrequency: 12 issues/year

OncoImmunology is a leading peer-reviewed journal published by Taylor & Francis Inc, dedicated to advancing the understanding of the dynamic interplay between the immune system and cancer. Established in 2012 and adopting an open access model since 2020, OncoImmunology provides a platform for high-quality research disseminated globally, with a notable focus on innovative therapies and immunotherapeutic strategies aimed at improving patient outcomes. The journal boasts an impressive impact in the field, holding Q1 rankings in both Immunology and Oncology categories for 2023, and it is recognized within the top-tier journals in its domain, reflected in its Scopus ranks and percentiles. With contributions from leading experts and a wide audience of researchers, clinicians, and advanced students, OncoImmunology not only facilitates scholarly dialogue but also addresses pivotal challenges in cancer treatment, making it an essential resource for those invested in the future of oncological and immunological research.

Science Immunology

Exploring the Depths of Immune Responses
Publisher: AMER ASSOC ADVANCEMENT SCIENCEISSN: 2470-9468Frequency: 12 issues/year

Science Immunology, published by the American Association for the Advancement of Science, is a leading journal in the field of immunology, recognized for its significant impact and rigor in advancing our understanding of immune responses and complex diseases. With an impressive impact factor that places it in the Q1 category of both immunology and allergy, as well as miscellaneous medicine, this journal is ranked #7 and #8 in their respective Scopus categories, reflecting its high-quality research output. Since its inception in 2016, Science Immunology has been at the forefront of interdisciplinary immunological research, fostering crucial insights that link immunology with pressing health challenges. The journal is committed to providing open access to its content, ensuring that groundbreaking findings are accessible to a global audience of researchers, professionals, and students. Its anthology not only addresses fundamental immunological mechanisms but also enhances the dialogue on translational applications and therapeutic interventions, solidifying its position as an essential resource within the scientific community.

CRITICAL REVIEWS IN IMMUNOLOGY

Fostering Critical Conversations in Immunology
Publisher: BEGELL HOUSE INCISSN: 1040-8401Frequency: 6 issues/year

CRITICAL REVIEWS IN IMMUNOLOGY, published by BEGELL HOUSE INC, is an essential journal in the field of immunology that has been contributing to the scientific discourse since 1980. With its ISSN 1040-8401 and E-ISSN 2162-6472, this journal provides a platform for critical analysis and comprehensive reviews that deepen understanding of immune responses and their implications in health and disease. Although currently categorized in the Q4 quartile for Immunology and Q3 for Immunology and Allergy, the journal's quality research and scholarly contributions are crucial for advancing knowledge within its fields—encompassing various aspects of innate and adaptive immunity. Researchers and professionals in immunology will find invaluable insights, aiding them in their quest for innovation and excellence, as the journal aims to foster interdisciplinary collaboration. While it does not operate on an open-access model, CRITICAL REVIEWS IN IMMUNOLOGY remains a significant resource for those dedicated to pushing the boundaries of immunology, with annual publications expected to last well into 2024 and beyond.

JOURNAL OF IMMUNOTHERAPY

Transforming Cancer Treatment with Groundbreaking Research
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1524-9557Frequency: 9 issues/year

JOURNAL OF IMMUNOTHERAPY, published by Lippincott Williams & Wilkins, is a premier journal dedicated to advancing the field of immunotherapy, a vital aspect of contemporary cancer research and treatment. With an ISSN of 1524-9557 and an E-ISSN of 1537-4513, this esteemed journal has been disseminating cutting-edge research since 1991 and continues to thrive with a convergence of knowledge leading into 2024. Recognized in the top Q2 quartile for fields such as Cancer Research, Immunology, and Allergy, as well as achieving a Q1 ranking in Pharmacology, the journal serves as a critical resource for researchers, clinicians, and students alike. Its robust impact is reflected in its competitive Scopus rankings across various categories, where it holds significant percentile standings. Highly regarded in the academic community for its rigor, the JOURNAL OF IMMUNOTHERAPY aims to provide a platform for innovative ideas, clinical findings, and experimental research that propels the science of immunotherapy forward. Although it does not offer open access, the journal ensures that its contents remain accessible and impactful for professionals in the field, fostering collaboration and knowledge exchange in an era where immunotherapy holds the promise for breakthroughs in patient care.

Immunity Inflammation and Disease

Elevating the discourse on therapeutic strategies for inflammatory diseases.
Publisher: WILEYISSN: Frequency: 12 issues/year

Immunity, Inflammation and Disease is a premier open-access journal published by WILEY, dedicated to advancing the field of immunology and allergy. Launched in 2013, this journal has established itself as a significant platform for researchers and professionals to disseminate high-quality research findings and innovative insights that address critical issues in immune responses and inflammatory diseases. With an impact factor that reflects its growing influence and a current ranking in Q3 for Immunology and Q2 for Immunology and Allergy, this journal serves a diverse audience keen on exploring cutting-edge developments. Researchers are encouraged to submit their work to share their findings with a global reach, foster collaboration, and enhance the understanding of immune mechanisms and therapeutic strategies. Accessible since its inception, Immunity, Inflammation and Disease is committed to open science, ensuring that vital research is freely available for the advancement of knowledge within the academic community and beyond.

Molecular Therapy Oncolytics

Exploring the Frontiers of Molecular Medicine in Oncology
Publisher: CELL PRESSISSN: 2372-7705Frequency: 1 issue/year

Molecular Therapy Oncolytics is an esteemed Open Access journal published by CELL PRESS, focusing on cutting-edge research in the fields of oncology, molecular medicine, and pharmacology. Established in 2014, the journal has quickly gained a prominent position in the academic community, reflected in its impressive Q1 and Q2 rankings across various categories including Cancer Research, Molecular Medicine, and Pharmacology. With an impactful presence in the UK and a strong international readership, it aims to disseminate significant advancements in therapeutic strategies targeted at cancer treatment and management. By providing a platform for peer-reviewed research, Molecular Therapy Oncolytics plays a critical role in bridging the gap between scientific innovation and clinical application, making it an invaluable resource for researchers, healthcare professionals, and students striving to contribute to the evolving landscape of oncology.

IMMUNOLOGICAL REVIEWS

Connecting Researchers to the Heart of Immunological Advances.
Publisher: WILEYISSN: 0105-2896Frequency: 8 issues/year

IMMUNOLOGICAL REVIEWS is a prestigious journal published by Wiley, renowned for its comprehensive and insightful contributions to the field of immunology. Established in 1969, this journal has become an essential resource for researchers, practitioners, and students interested in the latest advancements in immunological science, specifically focusing on both clinical and basic immunology as well as allergy studies. With an impressive Q1 ranking in both Immunology and Immunology and Allergy categories, and a prominent placement in the Scopus ranks (23/233 and 26/236 in their respective fields), this journal consistently showcases high-quality, peer-reviewed articles that significantly impact our understanding of immune responses. Although Open Access options are not available, the journal remains highly valuable, providing in-depth reviews and perspectives that foster further research and dialogue in immunological sciences. With a commitment to excellence, IMMUNOLOGICAL REVIEWS serves as a vital platform for disseminating knowledge, fostering scientific collaboration, and advancing the field toward innovative healthcare solutions.